What was the median progression-free survival of third-line therapy in PANTHEON?

Reconstructed medians (Months): OFF(after FOLFIRI) 2.0; FOLFIRI (after OFF) 2.0. See the published article for the official values.

What was the hazard ratio for progression-free survival of third-line therapy in PANTHEON?

The figure reports a hazard ratio of 0.71 (95% CI 0.32–1.58). TrialCurve's reconstruction gives 0.711.

What was the median time to failure of strategy in PANTHEON?

Reconstructed medians (Months): FOLFIRI 4.5; OFF 4.1. See the published article for the official values.

What was the hazard ratio for time to failure of strategy in PANTHEON?

The figure reports a hazard ratio of 0.7 (95% CI 0.41–1.2). TrialCurve's reconstruction gives 0.736.

What was the median overall survival from start of study in PANTHEON?

Reconstructed medians (Months): FOLFIRI 5.9; OFF 6.2. See the published article for the official values.

What was the hazard ratio for overall survival from start of study in PANTHEON?

The figure reports a hazard ratio of 0.95 (95% CI 0.54–1.66). TrialCurve's reconstruction gives 0.935.

Home / Trials

PANTHEON: reconstructed Kaplan–Meier curves

Updated 2026-09-25 · reconstructed by TrialCurve from a CC BY-licensed publication

Sequential therapy of refractory metastatic pancreatic cancer with 5-FU/LV/irinotecan (FOLFIRI) vs. 5-FU/LV/oxaliplatin (OFF). The PANTHEON trial (AIO PAK 0116). Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.

Publication	J Cancer Res Clin Oncol. 2024 Jul 1;150(7):332. doi: 10.1007/s00432-024-05827-x
DOI	10.1007/s00432-024-05827-x
Registry	—
Phase	—
Conditions	—
Interventions	—
Sponsor	—
Enrolment	—
Source licence	Figure published under CC BY 4.0

Progression-free survival of second-line therapy (primary endpoint) — Full analysis set

From figure panel a · validated against the values printed on the figure · curve source: vision model

Reconstructed from the published curve. Median: FOLFIRI 2.5 months; OFF 2.4 months. Survival at 6 months: FOLFIRI 16%; OFF 10%. Hazard ratio FOLFIRI vs OFF 0.83 (95% CI 0.47–1.48).

Arm	N	Events	Median (Months)
FOLFIRI	37	37	2.5
OFF	23	18	2.4

FOLFIRI vs OFF: reconstructed HR 0.83 (95% CI 0.47–1.48)

Landmark survival (reconstructed)

Time	FOLFIRI	OFF
3 mo	32.4%	15.6%
6 mo	16.2%	10.4%
9 mo	5.4%	—
12 mo	2.7%	—

Checks against the published figure

FOLFIRI median: printed 2.4, reconstructed 2.45 pass
OFF median: printed 2.4, reconstructed 2.42 pass
FOLFIRI events: printed 37, reconstructed 37 pass
FOLFIRI n: printed 37, reconstructed 37 pass
OFF events: printed 18, reconstructed 18 pass
OFF n: printed 23, reconstructed 23 pass
hazard ratio (direction inferred): printed 0.8, reconstructed 0.83 pass

Download pseudo-IPD (CSV)

Progression-free survival of third-line therapy — Full analysis set (patients receiving third-line therapy)

From figure panel b · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model

Reconstructed from the published curve. Median: OFF(after FOLFIRI) 2.0 months; FOLFIRI (after OFF) 2.0 months. Survival at 2 months: OFF(after FOLFIRI) 50%; FOLFIRI (after OFF) 50%. Hazard ratio OFF(after FOLFIRI) vs FOLFIRI (after OFF) 0.71 (95% CI 0.32–1.58).

Arm	N	Events	Median (Months)
OFF(after FOLFIRI)	18	17	2.0
FOLFIRI (after OFF)	10	10	2.0

OFF(after FOLFIRI) vs FOLFIRI (after OFF): reconstructed HR 0.71 (95% CI 0.32–1.58)

Landmark survival (reconstructed)

Time	OFF(after FOLFIRI)	FOLFIRI (after OFF)
2 mo	50.0%	50.0%
4 mo	11.1%	10.0%
6 mo	5.6%	—

Checks against the published figure

OFF(after FOLFIRI) median: printed 2, reconstructed 1.97 pass
FOLFIRI (after OFF) median: printed 2, reconstructed 1.97 pass
OFF(after FOLFIRI) events: printed 18, reconstructed 17 pass
OFF(after FOLFIRI) n: printed 18, reconstructed 18 pass
FOLFIRI (after OFF) events: printed 10, reconstructed 10 pass
FOLFIRI (after OFF) n: printed 10, reconstructed 10 pass
hazard ratio (direction inferred): printed 0.71, reconstructed 0.711 pass

Download pseudo-IPD (CSV)

Time to failure of strategy — Full analysis set

From figure panel c · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model

Reconstructed from the published curve. Median: FOLFIRI 4.5 months; OFF 4.1 months. Survival at 6 months: FOLFIRI 27%; OFF 17%. Hazard ratio FOLFIRI vs OFF 0.74 (95% CI 0.43–1.27).

Arm	N	Events	Median (Months)
FOLFIRI	37	36	4.5
OFF	23	22	4.1

FOLFIRI vs OFF: reconstructed HR 0.74 (95% CI 0.43–1.27)

Landmark survival (reconstructed)

Time	FOLFIRI	OFF
3 mo	62.2%	56.5%
6 mo	27.0%	17.4%
9 mo	18.9%	4.3%
12 mo	2.7%	—

Checks against the published figure

FOLFIRI median: printed 4.5, reconstructed 4.51 pass
OFF median: printed 4.1, reconstructed 4.05 pass
FOLFIRI events: printed 37, reconstructed 36 pass
FOLFIRI n: printed 37, reconstructed 37 pass
OFF events: printed 23, reconstructed 22 pass
OFF n: printed 23, reconstructed 23 pass
hazard ratio (direction inferred): printed 0.7, reconstructed 0.736 pass

Download pseudo-IPD (CSV)

Overall survival from start of study — Full analysis set

From figure panel d · validated against the values printed on the figure · curve source: vision model

Reconstructed from the published curve. Median: FOLFIRI 5.9 months; OFF 6.2 months. Survival at 6 months: FOLFIRI 48%; OFF 50%. Hazard ratio FOLFIRI vs OFF 0.93 (95% CI 0.53–1.64).

Arm	N	Events	Median (Months)
FOLFIRI	37	33	5.9
OFF	23	20	6.2

FOLFIRI vs OFF: reconstructed HR 0.93 (95% CI 0.53–1.64)

Landmark survival (reconstructed)

Time	FOLFIRI	OFF
6 mo	48.1%	50.2%
12 mo	21.0%	10.4%
18 mo	—	5.2%

Checks against the published figure

FOLFIRI median: printed 5.9, reconstructed 5.86 pass
OFF median: printed 5.9, reconstructed 6.18 pass
FOLFIRI events: printed 33, reconstructed 33 pass
FOLFIRI n: printed 37, reconstructed 37 pass
OFF events: printed 20, reconstructed 20 pass
OFF n: printed 23, reconstructed 23 pass
hazard ratio (direction inferred): printed 0.95, reconstructed 0.935 pass

Download pseudo-IPD (CSV)

About these data

Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.

Load these data in R or Python

# R
library(survival)
d <- read.csv("https://trialcurve.com/data/trials/pantheon-1.csv")
survfit(Surv(time, event) ~ arm, data = d)
coxph(Surv(time, event) ~ arm, data = d)

# Python
import pandas as pd
from lifelines import KaplanMeierFitter
d = pd.read_csv("https://trialcurve.com/data/trials/pantheon-1.csv")
for arm, g in d.groupby("arm"):
    KaplanMeierFitter().fit(g.time, g.event, label=arm).plot_survival_function()

Suggested citation: J Cancer Res Clin Oncol. 2024 Jul 1;150(7):332. doi: 10.1007/s00432-024-05827-x doi:10.1007/s00432-024-05827-x. Reconstructed data: TrialCurve (2026), https://trialcurve.com/trials/pantheon

Report a problem with these data

Related trials

GENERATE: Overall survival (planned interim analysis); Overall survival (updated analysis); Progress
NCI9673 (Part B): Overall survival; Progression-free survival
KHBO1401-MITSUBA: Overall survival; Progression-free survival
Convalescent plasma for severe COVID-19 in cancer patients: Overall survival (secondary endpoint)
ADIUVO: Overall survival; Recurrence-free survival
CONFIRM: Overall survival; Progression-free survival

Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.

Reconstruct a figure Browse all trials